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Abstract
Background: Although a majority of studies in cancer biomarker discovery claim to use proportional hazards regression 
(PHREG) to the study the ability of a biomarker to predict survival, few studies use the predicted probabilities obtained 
from the model to test the quality of the model. In this paper, we compared the quality of predictions by a PHREG model 
to that of a linear discriminant analysis (LDA) in both training and test set settings. 
Methods: The PHREG and LDA models were built on a 491 colorectal cancer (CRC) patient dataset comprised of demo-
graphic and clinicopathologic variables, and phenotypic expression of p53 and Bcl-2. Two variable selection methods, 
stepwise discriminant analysis and the backward selection, were used to identify the ﬁ  nal models. The endpoint of predic-
tion in these models was ﬁ  ve-year post-surgery survival. We also used linear regression model to examine the effect of bin 
size in the training set on the accuracy of prediction in the test set.
Results: The two variable selection techniques resulted in different models when stage was included in the list of variables 
available for selection. However, the proportion of survivors and non-survivors correctly identiﬁ  ed was identical in both of 
these models. When stage was excluded from the variable list, the error rate for the LDA model was 42% as compared to 
an error rate of 34% for the PHREG model.
Conclusions: This study suggests that a PHREG model can perform as well or better than a traditional classiﬁ  er such as 
LDA to classify patients into prognostic classes. Also, this study suggests that in the absence of the tumor stage as a vari-
able, Bcl-2 expression is a strong prognostic molecular marker of CRC. 
Keywords: predictive models, linear discriminant analysis, proportional hazards regression, colorectal cancer, survival.
Introduction 
One of the consequences of the arrival of high though-put technological platforms in biomarker discovery 
research and resultant generation of high-dimensional datasets has been a re-focusing of analysts’ atten-
tions on the quality of predictions from models and on measures of predictive accuracy. Studies that 
develop predictive models now routinely address the issues related to the validation of ﬁ  ndings by 
analyzing the ‘training’ and ‘test’ sets or utilize cross validation approaches like “leave one out cross 
validation”(1).
Classiﬁ  cation is a process which assigns objects to a category, and is routinely used in many scientiﬁ  c 
studies. Fisher and his contemporaries were the pioneers in the development of classiﬁ  ers such as the Linear 
discriminant analysis (LDA) and cluster analysis (2). The LDA uses the distance of an individual’s mean 
value from the estimated mean of a group in order to classify that individual into a group. The closer the Cancer Informatics 2007:3 116
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individual’s result is to a group’s mean value the 
greater is the probability of the individual belonging 
to that group. These classiﬁ  ers can easily be imple-
mented in commonly used statistical software tools, 
including SAS and S-Plus. 
PHREG models are the multivariable models 
that are most commonly used in studies that 
evaluate molecular markers to predict cancer prog-
nosis, or compare efﬁ  cacy of cancer therapies. This 
is because the outcome of interest in most cancer 
studies is time to an ‘event’ such as death, recur-
rence, or metastasis. PHREG is a semi-parametric 
model, which assesses the effect of various inde-
pendent variables on the time to an event of 
interest. One of the problems encountered in the 
accumulation of data on individuals over a time 
period is that patients are often either lost to follow 
up or with unknown outcomes. The contribution 
of these individuals to the model, as long as there 
is a credible data on them, is considered to be an 
advantage of the PHREG model which allows for 
‘censoring.’ The hazard ratios estimated by these 
models are also widely used, and easily interpreted 
both by researchers and clinicians. 
The objective of this study was to compare the 
predictions of a PHREG model of 5- year cancer-
speciﬁ  c mortality to that of the LDA. Since the 
PHREG model probability estimates are adjusted 
for censored individuals, we hypothesized that a 
classiﬁ  er based on predicted probabilities esti-
mated by PHREG would probably perform better 
than an LDA. Two separate variable selection 
techniques (stepwise discriminant analysis and 
backward selection) were used to identify ﬁ  nal 
models in both cases. We also examined the possi-
bility of identifying variables which can be used 
to predict the clinical outcome or aggressive 
behavior of CRC by clinicians well before the 
pathologic staging information is available. For 
this, we tested the molecular phenotypic markers, 
nuclear accumulation of p53 (p53
nac) and expression 
of Bcl-2, in models without the tumor stage variable 
to assess their prognostic value and compared to the 
value of the tumor stage in predicting survival of 
CRC patients. 
Patients and Methods
Patients
The institutional review boards of the University 
of Alabama at Birmingham (UAB) and its afﬁ  liated 
Birmingham Veterans Affairs (VA) Hospital 
approved this study. We identiﬁ  ed a total of 491 
patients from the UAB and VA Hospital tumor 
registries who had undergone surgical resection 
only for ‘ﬁ  rst primary’ CRC from 1981 through 
1993. None of these patients received any pre- or 
post-surgery chemo or radiation therapies for 
various reasons. We obtained the medical records 
including surgical pathology reports of these 
patients which were reviewed by two of the authors 
(CC and UM) to ascertain the key information. The 
patient cohort from both hospitals was under the 
care of a uniform group of physicians. 
Pathological features
In our study, two pathologists (NCJ and WEG) 
reviewed hematoxylin and eosin stained slides of 
all cases for the degree of histologic differentiation 
and graded as well, moderate, poor or undifferen-
tiated. Subsequently, we pooled well and moder-
ately differentiated tumors into a low grade group 
and poor and undifferentiated tumors into a high 
grade group (3). The pathologic staging was 
performed according to the criteria of the American 
Joint Commission on Cancer (4) using the informa-
tion extracted from the pathology reports. In our 
study, we pooled Stages I and II and Stage III and 
Stage IV into node negative and node positive 
categories, respectively. The International Clas-
siﬁ  cation of Diseases for Oncology (ICD-O) codes 
were used to specify anatomic location of the tumor 
(5). The anatomic sub-sites were grouped into the 
proximal colon, the distal colon and the rectum. 
Follow-up
Patients were followed by the UAB and VA tumor 
registries until their death or the date of the last 
documented contact within the study time frame. 
The tumor registries ascertain outcome (mortality) 
information directly from patients (or living rela-
tives) and from the physicians of the patients 
through telephone and mail contacts. This informa-
tion is further validated against State Death Lists. 
The tumor registries update follow-up information 
every six months and follow-up of our cohort 
ended in September 2006. There was only one 
individual who was censored due to loss to follow 
up in the test data set. All the other censored indi-
viduals are censored because they were alive for 
more than ﬁ  ve years at the last follow up. This 
quality of follow-up for all cause mortality allows Cancer Informatics 2007:3 117
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us to estimate the sensitivity and speciﬁ  city of the 
two models for 5 year all cause mortality with a 
great degree of accuracy.
Immunohistochemistry
Formalin-ﬁ  xed, parafﬁ  n-embedded archival tissues 
of CRCs were collected from the surgical pathology 
division of UAB and VA Hospitals. Immunohisto-
chemical staining and immunostaining evaluation 
of nuclear accumulation of p53 and Bcl-2 were 
described earlier (6–10). The molecular marker 
expression was dichotomized into high expressers 
and low expressers based on the cut-off values 
discussed below. For Bcl-2 expression, based on 
our prior studies (9, 11), 0.5 ISS was chosen as the 
cut-off value. We considered only tumor cells with 
distinct nuclear immunostaining for p53 as positive 
and considered the tumor positive only if ≥10% 
positivity of all malignant cells in a tissue section 
as described earlier (7). 
Statistical analyses
The outcome variable LDA model was a binary 
variable indicating cancer-speciﬁ  c survival (or not) 
ﬁ  ve years post-surgery for CRC. Time to Cancer-
speciﬁ  c death was the outcome for the PHREG 
model. The censoring variable for the PHREG model 
was a dichotomous variable by the PHREG model  
that identiﬁ  ed individuals who had died as a result 
of CRC in the ﬁ  ve years after surgery. Individuals 
who died within ﬁ  ve years due to other causes or 
those who lived more than ﬁ  ve years were consid-
ered censored. The training set had data on 234   
non-Hispanic Caucasians (80% of initial 292), and 
159 (80% of 199) African-Americans who were 
randomly selected from 491 patients. The 
remaining individuals formed the test set. Forty-
one percent (162) of individuals in the training data 
set had the event of interests and 59 % were 
censored. The proportion of censored individuals 
in the test data set was 39%. The variables available 
for inclusion in the model were, age (< 65 vs. ≥ 65 
years), race (non-Hispanic Caucasians vs. African-
Americans), tumor stage (I & II vs. III & IV or 
node negative vs. node positive), tumor differen-
tiation (low grade vs. high grade), location of tumor 
(proximal colon, distal colon and rectum), and 
p53nac and Bcl-2 expression. All variables were 
dichotomized for an easier interpretation of the 
hazard ratios. Appropriate cut-points for both the 
molecular markers as well as continuous variables 
such as age based on this data have been identiﬁ  ed 
in previous published studies based on this data 
(6–10). We ﬁ  rst used a bootstrapped stepwise 
discriminant analysis as a variable selection tech-
nique. This technique is loosely based on the pre-
validation technique described by Tibshirani and 
Efron (12). We have previously described this 
method in our analysis of the data generated by 
Surface Enhanced Laser Absorption/Desorption 
Ionization—Time of Flight (SELDI-TOF) (13). In 
this, 75% of the training set was randomly selected 
and subjected to a stepwise discriminant analysis 
procedure to identify those variables that could 
best separate the two groups (those who did or did 
not survive ﬁ  ve years post-surgery). This list of 
variables was stored and the step was iterated 1000 
times. Variables that occurred in at least 500 of the 
1000-stored lists were selected for inclusion in the 
ﬁ  nal LDA models. The process was ﬁ  rst run by 
including the tumor stage in the list of variables in 
the stepwise discriminant procedure, and then 
again after omitting the tumor stage from the list 
of variables available for selection. Since Stepwise 
Discriminant Analysis does not account for 
censoring, this iterative re-sampling technique 
provides a mechanism for censored and uncensored 
individuals to contribute equally in the selection 
of a ﬁ  nal model. The backward selection technique 
available in SAS (V9.1.3)®’s Proc PHREG was 
used as a second variable selection technique. Five 
year survival probabilities were estimated using 
both LDA and PHREG. In SAS (V9.1.3)® Proc 
Discrim was used to classify the individuals using 
the LDA. With three dichotomous variables in the 
model, an individual will have one of eight possible 
combinations of the variables. A categorical vari-
able that identiﬁ  ed these eight combinations was 
created and each individual was assigned to one 
of the categories. PHREG estimated a predicted 
probability for survival for each of the eight 
categories based on the model built on the training 
set. A similar procedure was followed for the two 
variable models which only had four possible 
combinations of the two dichotomous variables. 
In both, the LDA and the PHREG, if an individu-
al’s predicted probability of survival beyond ﬁ  ve 
years was ≤ 0.5, that individual was considered a 
non-survivor. The proportion of survivors correctly 
identiﬁ  ed (speciﬁ  city), the proportion of non-
survivors correctly identiﬁ  ed (sensitivity), and the 
average error rate of the model (the average 
proportion of incorrectly identiﬁ  ed survivors and Cancer Informatics 2007:3 118
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non-survivors) were used to compare the quality 
of the models. We also examined the effect of the 
proportion of individuals in a bin in the training 
set to the accuracy of the prediction in that 
category in the test set utilizing the linear regres-
sion method. A bin is a particular combination of 
the variables in the model; e.g. in model 1 ( Table 1) 
all individuals with a tumor that is a stage 1 or 2, 
negative for Bcl-2, and well differentiated belong 
to one bin (row 1, Table 1). Thus each row of 
Table 1 deﬁ  nes a bin for the particular model. The 
proportion of correct predictions in both LDA and 
PHREG were very close in most models in most 
bins. We have only demonstrated the effect of bin 
size on prediction accuracy based on the PHREG 
model.
Table 1. Predicted Probabilities for the Combinations of Variables in PHREG and LDA. 
Model 1: Predictors - Tumor Stage, Bcl-2 & Tumor grade; Variable 
    Selection Technique—PHREG Backward Selection
Combination of Variables
a
(Tumor stage
b, tumor grade
c & Bcl-2 expression
d)  PHREG
e  LDA
e
I & II + Low + Bcl-2 negative  0.69  0.72
III & IV + Low + Bcl-2 negative  0.27  0.35
I & II + High + Bcl-2 negative  0.55  0.38
I & II + Low + Bcl-2 positive  0.78  0.86
III & IV + High + Bcl-2 negative  0.11  0.07
I & II + High + Bcl-2 positive  0.67  0.53
III & IV + Low + Bcl-2 positive  0.41  0.47
III & IV + High + Bcl-2 positive  0.23  0.08
% deaths correctly predicted 76  76
% survivors correctly predicted 73  73
% Error rate 25.5  25.5
Model 2 :  Predictors - Tumor Stage & Bcl-2; Variable Selection Technique 
      —Iterative Stepwise Discriminant Analysis
Combination of Variables
f
(Tumor stageb & Bcl-2 expression
d)  PHREG
e  LDA
e
I & II + Bcl-2 negative  0.68  0.71
III & IV + Bcl-2 negative  0.24  0.26
I & II + Bcl-2 positive  0.77  0.82
III & IV + Bcl-2 positive  0.37  0.41
% deaths correctly predicted 76  76
% survivors correctly predicted 73  73
% Error rate 25.5  25.5
Model 3 : Predictors - Bcl-2 & Tumor grad; Variable Selection Technique—PHREG Backward Selection 
& Iterative Stepwise Discriminant Analysis
Combination of Variables
g
(Tumor grade
c & Bcl-2 expression
d)  PHREG
e LDA
e
Low + Bcl-2 negative  0.49  0.56
Low + Bcl-2 positive  0.67  0.74
High + Bcl-2 negative  0.24  0.15
High + Bcl-2 positive  0.44  0.22
% deaths correctly predicted 79  29
% survivors correctly predicted 53  87
% Error rate  34 42
a Variables were selected by the backward selection procedure in Proc PHREG in SAS.
b Tumor stage was dichotomized as node negative (Stage I + II) and node positive (Stage III + IV).
c Tumor differentiation dichotomized as  low grade and high grade.
d Phenotypic expression of Bcl-2 dichotomized  as negative and positive as described in the methods section
e Predicted outcome of survival probability beyond 5 years after surgery for the combination of variables. 
f Variables were selected using iterative bootstrapping sampling method described in the methods section.
g Two variable selection procedures were tried (iterative bootstrapping and the backward selection)  and the tumor stage was excluded 
from both the models. Cancer Informatics 2007:3 119
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Results
This variable selection procedure using an iterative 
stepwise discriminant analysis resulted in ﬁ  nal 
models that had two predictors (tumor stage and 
Bcl-2 expression) when tumor stage was included 
in the initial list and two predictors (Bcl-2, tumor 
differentiation) when stage was excluded. When 
the backward selection procedure in PHREG was 
used as a variable selection technique, the two ﬁ  nal 
models were, a three variable model (tumor stage, 
Bcl-2, and tumor differentiation) when tumor stage 
was included in the variable list, and a two variable 
model (Bcl-2 and tumor differentiation) when stage 
was excluded. Table 2 displays the results of the 
PHREG models ﬁ  t to the training data. Bcl-2 was 
a signiﬁ  cant predictor of ﬁ  ve-year survival in all 
the models in this study. It was identiﬁ  ed as a 
signiﬁ  cant predictor in models that included tumor 
stage as well as those that excluded it. It was iden-
tiﬁ  ed as a signiﬁ  cant variable by both types of 
variable selection techniques. When the tumor 
stage was included in the list of possible predictors, 
as expected both variable selection techniques 
selected tumor grade as a signiﬁ  cant predictor of 
ﬁ  ve-year survival. The PHREG backward selection 
procedure identiﬁ  ed tumor differentiation in addi-
tion to tumor stage and Bcl-2 expression as a 
signiﬁ  cant predictor of ﬁ  ve-year survival. Table 1 
displays the probability of survival beyond ﬁ  ve 
years as predicted by the PHREG model, and the 
LDA model, for an individual with a given combi-
nation of variables. This table is divided into three 
sections for the three ﬁ  nal models that resulted 
from the two variable selection procedures used. 
The table also displays the survivors and non-
survivors correctly identified by the different 
models. 
The regression of the proportion of correct 
predictions in each bin in the test set versus the 
proportion of individuals in the bin in the training 
set is shown in Figure 1. The correlation coefﬁ  cient 
is 0.451, with a p-value of 0.07. The Beta coefﬁ  -
cient for the proportion of individuals in a particular 
bin in the training set is 0.4632, suggesting that 
unit increase in the proportion of the individuals 
in a bin in the training set will result in an increase 
in the accuracy of prediction in the test set. 
Discussion
The current study has demonstrated that a PHREG 
model built on a training set can be utilized to clas-
sify individuals in a test set. This study used both 
the traditional stepwise procedures generally used 
for PHREG models to select the variables to be 
entered into the model as well as an iterative tech-
nique that used stepwise discriminant analysis as 
variable selection techniques. At this point of time, 
this method, using a PHREG model to estimate 
predictability, may be limited to models built on 
dichotomized variables; however, our studies to 
implement this approach to continuous variables 
are currently in progress. 
In our current study, we have considered the 
predictions of Cox’s PHREG and LDA multivari-
able models. A proper comparison of these models 
requires the comparison of predictions based on 
all the variables in the model. The accuracy of the 
predictions in the test set in this study was assessed 
by comparing the predicted probability of death to 
the observed truth. This is a more accurate test for 
the predictive quality of a model than the visual 
determination that considers whether the predicted 
curves are farther apart or closer together. There-
Table 2. Signiﬁ  cant Variables Obtained in a Proportional Hazards Regression Model. 
  PHREG model including tumor stage as a variable  PHREG model excluding tumor stage    
    as a variable
Variables
a  HR (95% CI)  P value  Variables
a  HR (95% CI)  P value
Tumor stage
b  3.60 (2.58 – 5.027)  <0.0001
Bcl-2 expression
c  0.67 (0.493 – 0.92)  <0.0138  Bcl-2 expression
c  0.58 (0.42 – 0.79)  0.0006
Tumor  1.63 (1.11 – 2.38)  0.0112  Tumor  2.03 (1.39 – 2.95)  0.0002 
differentiation
d     differentiation
d
HR: hazard ratio; CI: conﬁ  dence interval 
a Variables were selected using the stepwise discriminant analysis as described in the methods section. 
b Stage dichotomized as node negative (Stage I +II) and node positive (Stage III + IV).
c Phenotypic expression of Bcl-2 dichotomized  as negative and positive.
d Tumor differentiation dichotomized as  low grade and high grade.Cancer Informatics 2007:3 120
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fore, the current study has focused on comparing 
these two techniques that are commonly accessible 
to the data analysts in routinely used statistical 
software applications, including SAS and S-Plus, 
for the analysis of biomedical databases.
In the models that included TNM stage (depth 
of tumor, pT; regional lymph node metastasis, 
pN; and distant metastasis, M), the predicted 
probabilities from these two models, the PHREG 
and LDA, were very similar to each other. In fact 
the classiﬁ  cation of individuals based on these 
estimated probabilities was identical, i.e. PHREG 
and LDA identiﬁ  ed the same individuals as survi-
vors and non-survivors. This ﬁ  nding was contrary 
to our expectations; because one would expect 
that the PHREG with its ability to allow for 
censoring in the training dataset would perform 
better in predicting the ﬁ  ve-year survival than the 
LDA which has no mechanism to adjust for 
censoring. However, in the models that excluded 
tumor stage, PHREG model did perform better 
than the LDA in predicting non-survivors. The 
PHREG model identiﬁ  ed individuals that were 
likely to die in ﬁ  ve years with a much better 
accuracy than the LDA model. One explanation 
for this observation is that the strength of the 
prognostic value of TNM stage overrides any 
beneﬁ  ts that accrue from the censoring mecha-
nism in PHREG. However, in the absence of 
tumor stage, as expected, the predicted probabil-
ities from PHREG allowed better identiﬁ  cation 
of survivors and non-survivors. This is an impor-
tant finding specifically for prognostic variables 
such as molecular marker, gene expression or 
protein expression data. Most of these variables 
are expected to have modest individual prog-
nostic effects. In models that seek to predict 
survival/ recurrence using such variables, this 
study suggests that the predicted probabilities 
from PHREG are better at classifying the prog-
nosis of an individual with yet unknown conse-
quences. 
Additional signiﬁ  cant ﬁ  nding of this study is 
that Bcl-2 expression as a strong predictor of 
ﬁ  ve-year survival in CRC patients. Speciﬁ  cally, 
these ﬁ  ndings have far reaching clinical implica-
tions in the treatment of CRC particularly in 
predicting the outcome of patients who undergo 
the excisional biopsy as therapy. Because, infor-
mation on all components of TNM staging can 
not be obtained from histologic assess of biopsy 
specimens; thus, these ﬁ  ndings might be useful 
in assessing the aggressiveness of the tumor at 
the time of biopsy. 
Figure 1. Accuracy of Prediction in Test Set versus Bin Size in Training Set. The X-axis represents proportion of true deaths and true 
survivors accurately predicted in each bin in the test data set. The y-axis represents the proportion of individuals in each bin in the training 
data set. A bin is a particular combination of the variables in the model; e.g. All individuals with tumor stage I or II, negative for Bcl-2 expres-
sion, and with well differentiated tumors belong to one bin.
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Currently, treatment decisions are made based 
on clinical and pathologic stage of CRC; however, 
these features may not be the best indicators of 
prognosis, since groups of patients with tumors of 
identical stage have different treatment responses 
and outcomes. In fact, the TNM stage is probably 
more of a reﬂ  ection on how long a tumor has been 
developing rather than the biological features 
which lead to aggressiveness of tumors (14). There-
fore, more recent studies have focused on devel-
oping predictive/prognostic molecular markers in 
CRC which mirror the biology of lesions. 
However, no marker used to predict the responses 
of patients to speciﬁ  c therapies (predictive) or 
assess their survival (prognostic) has been univer-
sally accepted to be clinically useful due to contra-
dictory results. These controversies were due to 
variations in techniques used to assess the status 
of molecular markers, treatment modalities, under-
powered study populations, admixture of different 
proportions of tumors with different pathologic 
stages, etc. Therefore, to identify markers which 
predict the clinical outcomes with greater accuracy, 
our group has developed large CRC databases and 
have previously demonstrated the potential value 
of p53
nac, Bcl-2, MUC1 and p27
kip-1 expression in 
predicting the survival of subgroups of patients 
with CRC (7, 9, 15, 16). 
In the initial training set, p53
nac was not identi-
ﬁ  ed as a potential prognostic molecular marker. 
This is most likely because of p53
nac has been 
identiﬁ  ed as a prognostic molecular maker only 
for a subset of CRCs, speciﬁ  cally for proximal 
colonic adenocarcinomas from non-Hispanic 
Caucasian patients (17). Similarly, the hazard ratio 
for low Bcl-2 might have been higher if speciﬁ  ed 
subsets of tumors had been evaluated. Speciﬁ  cally, 
Bcl-2 expression does not seem to be as strong a 
prognostic biomarker in African-American patients 
(11). 
For the successful implementation of this 
method of predictability, one should consider the 
standard issues of the predictive modeling 
processes. Since the number of variables in the 
model increases, the number of possible combina-
tions increases, and the number of individuals with 
each combination will decrease. This increases 
the possibility that the predicted probabilities are 
less stable (have a larger variance), which in turn 
could reduce the predictive quality of a model. As 
the number of variables increase the sample size 
in the training set needs to be sufﬁ  ciently larger 
in order to ensure the reliability of this model to 
predict probability of patient survival. We have 
tried to demonstrate this fact by using the data 
available to us in this study. Given the eight bins 
in the 3-variable model and 4 bins each in the two 
two-variable models, we had only 16 data points 
to ﬁ  t this model. In order to see a statistically 
signiﬁ  cant correlation with 80% power the corre-
lation between the two variables in the regression 
would have to have been at least 0.80. Figure 1 
shows that that the accuracy of predictions in the 
test set is a function of the bin size in the training. 
The p-value ( p = 0.07) of the correlation between 
bin size and accuracy in this small sample example, 
illustrates the importance not only of having a 
sufﬁ  cient proportion of individuals in a each bin 
in the training set. 
The current study has built models on these CRC 
databases to test the ability of the PHREG and LDA 
models in predicting probabilities. The ﬁ  ndings of 
this study have demonstrated the usefulness of 
PHREG models in building classiﬁ  ers. The accuracy 
of the classiﬁ  cation by PHREG was better than the 
LDA classiﬁ  cation in the absence of the TNM stage 
variable. This study suggests that a classiﬁ  er with 
modest, but important prognostic, effects the ability 
of the PHREG model to use information from 
censored individuals improves the predictive quality 
of the model. Based on this study, it is reasonable 
to conclude that appropriate model variable selec-
tion has a signiﬁ  cant effect on the predictive ability 
of the model. Additionally, these studies have iden-
tiﬁ  ed clinically important ﬁ  ndings that patient age 
as a signiﬁ  cant prognostic indicator even in the 
models which included tumor stage as a variable. 
These ﬁ  ndings also suggest that it might be possible 
to use expression of Bcl-2 as a molecular marker to 
predict the patient prognosis when the information 
on tumor stage (TNM) is not available; speciﬁ  cally, 
useful in assessing the aggressiveness of the tumor 
at the time of biopsy.
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